Literature DB >> 3052780

Expression of c-myc oncogene product and ras family oncogene products in various human malignant lymphomas defined by immunohistochemical techniques.

S Mitani1, I Sugawara, H Shiku, S Mori.   

Abstract

The authors studied the expression of c-myc and ras family oncogene products in 43 cases of malignant lymphoma (ML) using the immunoperoxidase method. Unfixed frozen sections of lymph nodes from four patients with Hodgkin's disease and 39 with non-Hodgkin's lymphoma, together with normal lymph nodes, were studied by the avidin-biotin-peroxidase complex (ABC) technique. Two monoclonal antibodies, MYC-2 raised against recombinant human c-myc protein (reacting specifically with the c-myc products P62 and P67) and RASK-4 (raised against recombinant P21 and reacting specifically with ras-family product P21) were used. The c-myc product was detected in nuclei of ML cells and some normal, mainly germinal center, lymphocytes. When the staining intensity shown by normal germinal-center lymphocytes was graded as positive (+) or weakly positive (+/-), a very intensely positive reaction ( to ++) was observed in 37 cases (86%) of ML, a positive reaction (+) in four cases (9.3%), and a weakly positive reaction (+/-) in two cases (4.7%). The ras family oncogene product reaction was intensely positive (++) in two cases (4.7%), positive (+) in 16 cases (37.2%), weakly positive (+/-) in 13 cases (30.2%), and negative in 12 cases (27.9%). Western blot analysis confirmed an elevated level of c-myc products in two cases, which showed intense MYC-2 staining, and of ras family products in one case, which demonstrated intense RASK-4 staining. The enhanced expression of these gene products may play an important role in lymphomagenesis of such cases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052780     DOI: 10.1002/1097-0142(19881115)62:10<2085::aid-cncr2820621003>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Expression of c-myc and bcl-2 oncogene products in Reed-Sternberg cells independent of presence of Epstein-Barr virus.

Authors:  N M Jiwa; P Kanavaros; P van der Valk; J M Walboomers; A Horstman; W Vos; H Mullink; C J Meijer
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

2.  Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.

Authors:  F M Raaphorst; F J van Kemenade; T Blokzijl; E Fieret; K M Hamer; D P Satijn; A P Otte; C J Meijer
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

3.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.

Authors:  Alice C Fan; Debabrita Deb-Basu; Mathias W Orban; Jason R Gotlib; Yasodha Natkunam; Roger O'Neill; Rose-Ann Padua; Liwen Xu; Daryl Taketa; Amy E Shirer; Shelly Beer; Ada X Yee; David W Voehringer; Dean W Felsher
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

4.  The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.

Authors:  Elizabeth A Raetz; Sherrie L Perkins; Marlee A Carlson; Kevin P Schooler; William L Carroll; David M Virshup
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

5.  p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas.

Authors:  P Korkolopoulou; J Oates; C Kittas; J Crocker
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

6.  Distribution of c-yes-1 gene product in various cells and tissues.

Authors:  K Sugawara; I Sugawara; J Sukegawa; T Akatsuka; T Yamamoto; M Morita; S Mori; K Toyoshima
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

7.  Increased expression of ras genes in non-Hodgkin's lymphomas is not associated with oncogenic activation of those genes by point mutation.

Authors:  K Hamatani; Y Nagata; M Abe; K Abe; H Toki; S Ikeda; E Nakayama; H Shiku
Journal:  Jpn J Cancer Res       Date:  1989-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.